170 related articles for article (PubMed ID: 38805937)
21. Targeting Histone Methylation in Cancer.
McCabe MT; Mohammad HP; Barbash O; Kruger RG
Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
[TBL] [Abstract][Full Text] [Related]
22. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
23. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X; Jiang XJ; Fang ZM
Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
[TBL] [Abstract][Full Text] [Related]
24. Cancer treatment of the future: inhibitors of histone methyltransferases.
Spannhoff A; Sippl W; Jung M
Int J Biochem Cell Biol; 2009 Jan; 41(1):4-11. PubMed ID: 18773966
[TBL] [Abstract][Full Text] [Related]
25. Histone modification therapy of cancer.
Biancotto C; Frigè G; Minucci S
Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
[TBL] [Abstract][Full Text] [Related]
26. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.
Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M
ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196
[TBL] [Abstract][Full Text] [Related]
27. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.
Verma SK; Knight SD
Future Med Chem; 2013 Sep; 5(14):1661-70. PubMed ID: 24047271
[TBL] [Abstract][Full Text] [Related]
28. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
[TBL] [Abstract][Full Text] [Related]
29. SMYD5 is a histone H3-specific methyltransferase mediating mono-methylation of histone H3 lysine 36 and 37.
Aljazi MB; Gao Y; Wu Y; He J
Biochem Biophys Res Commun; 2022 Apr; 599():142-147. PubMed ID: 35182940
[TBL] [Abstract][Full Text] [Related]
30. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
[TBL] [Abstract][Full Text] [Related]
31. Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4.
Gauthier N; Caron M; Pedro L; Arcand M; Blouin J; Labonté A; Normand C; Paquet V; Rodenbrock A; Roy M; Rouleau N; Beaudet L; Padrós J; Rodriguez-Suarez R
J Biomol Screen; 2012 Jan; 17(1):49-58. PubMed ID: 21940714
[TBL] [Abstract][Full Text] [Related]
32. The histone H3K36 methyltransferase MES-4 acts epigenetically to transmit the memory of germline gene expression to progeny.
Rechtsteiner A; Ercan S; Takasaki T; Phippen TM; Egelhofer TA; Wang W; Kimura H; Lieb JD; Strome S
PLoS Genet; 2010 Sep; 6(9):e1001091. PubMed ID: 20824077
[TBL] [Abstract][Full Text] [Related]
33. Structure and function of histone H3 lysine 9 methyltransferases and demethylases.
Krishnan S; Horowitz S; Trievel RC
Chembiochem; 2011 Jan; 12(2):254-63. PubMed ID: 21243713
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.
Tsai CT; So CW
Oncogene; 2017 Mar; 36(13):1753-1759. PubMed ID: 27593928
[TBL] [Abstract][Full Text] [Related]
35. Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors.
Milite C; Feoli A; Viviano M; Rescigno D; Mai A; Castellano S; Sbardella G
ChemMedChem; 2016 Aug; 11(16):1680-5. PubMed ID: 27411844
[TBL] [Abstract][Full Text] [Related]
36. Recent Advances in Chemical Tools for the Regulation and Study of Protein Lysine Methyltransferases.
Hirano T; Mori S; Kagechika H
Chem Rec; 2018 Dec; 18(12):1745-1759. PubMed ID: 30079624
[TBL] [Abstract][Full Text] [Related]
37. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
[TBL] [Abstract][Full Text] [Related]
38. Covalent inhibition of NSD1 histone methyltransferase.
Huang H; Howard CA; Zari S; Cho HJ; Shukla S; Li H; Ndoj J; González-Alonso P; Nikolaidis C; Abbott J; Rogawski DS; Potopnyk MA; Kempinska K; Miao H; Purohit T; Henderson A; Mapp A; Sulis ML; Ferrando A; Grembecka J; Cierpicki T
Nat Chem Biol; 2020 Dec; 16(12):1403-1410. PubMed ID: 32868895
[TBL] [Abstract][Full Text] [Related]
39. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats.
Pogribny IP; Ross SA; Tryndyak VP; Pogribna M; Poirier LA; Karpinets TV
Carcinogenesis; 2006 Jun; 27(6):1180-6. PubMed ID: 16497704
[TBL] [Abstract][Full Text] [Related]
40. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.
Wang Z; Patel DJ
Q Rev Biophys; 2013 Nov; 46(4):349-73. PubMed ID: 23991894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
